Skip to main content

Advertisement

SpringerLink
Log in

Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Angiogenesis and lymphangiogenesis are key components of non-small cell lung cancer (NSCLC) tumor growth and metastatic spread; however, the prognostic and predictive role of angiogenic and lymphangiogenic biomarkers remains controversial for NSCLC patients. We assessed VEGF, VEGFC, VEGFD, VEGFR3 protein expression, tumor microvessel, and lymphatic vessel (LmVD) density by immunohistochemistry in 103 NSCLC; biomarkers were analyzed individually as well as multiplexed with each other. No correlations were identified between VEGF, VEGFC, VEGFD, or LmVD and clinical characteristics. VEGFR3 was correlated with VEGFC (p = 0.03), VEGFD (p < 0.0001), and intratumor LmVD (p = 0.03). Tumors that did not express VEGFR3 had a worse prognosis (log rank p = 0.03). VEGF was significantly correlated with survival in adenocarcinomas (log rank p = 0.014) but not in squamous cell carcinomas (log rank p = 0.5). Multivariate Cox regression analysis confirmed the independent prognostic potential of VEGFR3 (hazard ratio (HR) = 0.05; 95% confidence intervals (CI) = 0.008–0.32, p = 0.002) for all patients and VEGF (HR = 8.69, 95% CI = 1.4–53.69, p = 0.02) for adenocarcinomas. When biomarkers were multiplexed, only stage and VEGFC expression were independent predictors of survival for all patients. Weighted expression of VEGFC, VEGFR3, and stage was used to build a prognostic classifier for stage I–IIIA patients; patients in the low risk group had prolonged survival compared with high risk patients (log rank p = 0.02). There was no association between biomarkers and early recurrence or response to treatment. Angiogenic and lymphangiogenic biomarkers studied define subgroups of patients at high risk and may be useful for prognostic stratification of NSCLC patients especially those with early stage disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410. doi:10.1038/nrc1093

    Article  PubMed  CAS  Google Scholar 

  2. Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2(11):562–577. doi:10.1038/ncponc0342

    Article  PubMed  CAS  Google Scholar 

  3. Ferrara N, Gerber HP, LeCouter J (2003) The biology of vegf and its receptors. Nat Med 9(6):669–676. doi:10.1038/nm0603-669

    Article  PubMed  CAS  Google Scholar 

  4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. doi:10.1056/NEJMoa061884

    Article  PubMed  CAS  Google Scholar 

  5. El-Chemaly S, Levine SJ, Moss J (2008) Lymphatics in lung disease. Ann NY Acad Sci 1131:195–202. doi:10.1196/annals.1413.017

    Article  PubMed  Google Scholar 

  6. Achen MG, Stacker SA (2008) Molecular control of lymphatic metastasis. Ann NY Acad Sci 1131:225–234. doi:10.1196/annals.1413.020

    Article  PubMed  CAS  Google Scholar 

  7. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2(8):573–583. doi:10.1038/nrc863

    Article  PubMed  CAS  Google Scholar 

  8. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I, Dome B (2005) Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11(20):7344–7353

    Article  PubMed  CAS  Google Scholar 

  9. Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, Yokomise H (2008) The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 44(7):1057–1067

    Article  PubMed  CAS  Google Scholar 

  10. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094–1103. doi:10.1097/JTO.0b013e3181a97e31

    Article  PubMed  Google Scholar 

  11. de Santa C, Pau E, Arias FC, Caso Pelaez E, Munoz Molina GM, Sanchez Hernandez I, Muguruza Trueba I, Moreno Balsalobre R, Sacristan Lopez S, Gomez Pinillos A, del Val Toledo Lobo M (2009) Prognostic significance of the expression of vascular endothelial growth factors a, b, c, and d and their receptors r1, r2, and r3 in patients with nonsmall cell lung cancer. Cancer 115(8):1701–1712

    Article  Google Scholar 

  12. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) World health organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press, Lyon

    Google Scholar 

  13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92(3):205–216

    Article  PubMed  CAS  Google Scholar 

  14. Adachi Y, Nakamura H, Kitamura Y, Taniguchi Y, Araki K, Shomori K, Horie Y, Kurozawa Y, Ito H, Hayashi K (2007) Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-d2-40 antibody is correlated with lymphatic invasion or lymph node metastases. Pathol Int 57(4):171–177

    Article  PubMed  CAS  Google Scholar 

  15. Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM (2009) Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol 4(4):463–471. doi:10.1097/JTO.0b013e3181991d18

    Article  PubMed  Google Scholar 

  16. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y (2003) Clinical significance of vascular endothelial growth factor c and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97(2):457–464. doi:10.1002/cncr.11073

    Article  PubMed  CAS  Google Scholar 

  17. Bo C, Xiaopeng D, Chuanliang P, Xiaogang Z (2009) Expression of vascular endothelial growth factors c and d correlates with lymphangiogenesis and lymph node metastasis in lung adenocarcinoma. Thorac Cardiovasc Surg 57(5):291–294. doi:10.1055/s-0029-1185625

    Article  PubMed  Google Scholar 

  18. Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, Vassy R, Czernichow S, Letoumelin P, Breau JL, Bernaudin JF, Kraemer M (2007) Vascular endothelial growth factor-c and its receptor vegfr-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung cancer (Amsterdam, Netherlands) 58(2):205–213

    Google Scholar 

  19. Maekawa S, Iwasaki A, Shirakusa T, Enatsu S, Kawakami T, Kuroki M, Kuroki M (2007) Correlation between lymph node metastasis and the expression of vegf-c, vegf-d and vegfr-3 in t1 lung adenocarcinoma. Anticancer Res 27(6A):3735–3741

    PubMed  CAS  Google Scholar 

  20. Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, Satoh M, Sato N (2005) Clinical significance of vascular endothelial growth factor-c and vascular endothelial growth factor receptor 3 in patients with t1 lung adenocarcinoma. Cancer 104(8):1668–1677

    Article  PubMed  CAS  Google Scholar 

  21. Chen F, Takenaka K, Ogawa E, Yanagihara K, Otake Y, Wada H, Tanaka F (2004) Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer. Clin Cancer Res 10(24):8548–8553

    Article  PubMed  CAS  Google Scholar 

  22. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG (2007) Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 8(6):488–499. doi:10.1016/S1470-2045(07)70145-6

    Article  PubMed  Google Scholar 

  23. Sun JG, Wang Y, Chen ZT, Zhuo WL, Zhu B, Liao RX, Zhang SX (2009) Detection of lymphangiogenesis in non-small cell lung cancer and its prognostic value. J Exp Clin Cancer Res 28:21

    Article  PubMed  Google Scholar 

  24. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355(9202):479–485. doi:10.1016/S0140-6736(00)82038-3

    Article  PubMed  CAS  Google Scholar 

  25. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893–898. doi:10.1038/nature06358

    Article  PubMed  CAS  Google Scholar 

  26. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362(9382):433–439. doi:10.1016/S0140-6736(03)14068-8

    Article  PubMed  CAS  Google Scholar 

  27. Donnem T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund LT, Bremnes RM (2009) Vegf-a and vegfr-3 correlate with nodal status in operable non-small cell lung cancer: Inverse correlation between expression in tumor and stromal cells. Lung cancer (Amsterdam, Netherlands) 63(2):277–283

    Google Scholar 

  28. Ko YH, Jung CK, Lee MA, Byun JH, Kang JH, Lee KY, Jo KH, Wang YP, Hong YS (2008) Clinical significance of vascular endothelial growth factors (vegf)-c and -d in resected non-small cell lung cancer. Cancer Res Treat 40(3):133–140

    Article  PubMed  Google Scholar 

  29. Takizawa H, Kondo K, Fujino H, Kenzaki K, Miyoshi T, Sakiyama S, Tangoku A (2006) The balance of vegf-c and vegfr-3 mrna is a predictor of lymph node metastasis in non-small cell lung cancer. Br J Cancer 95(1):75–79

    Article  PubMed  CAS  Google Scholar 

  30. Takanami I (2006) Lymphatic microvessel density using d2-40 is associated with nodal metastasis in non-small cell lung cancer. Oncol Rep 15(2):437–442

    PubMed  Google Scholar 

  31. Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T, Strittmatter K, Stacker SA, Achen MG, Alitalo K, Christofori G (2007) Distinct roles of vascular endothelial growth factor-d in lymphangiogenesis and metastasis. Am J Pathol 170(4):1348–1361

    Article  PubMed  CAS  Google Scholar 

  32. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K (2005) Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65(11):4739–4746. doi:10.1158/0008-5472.CAN-04-4576

    Article  PubMed  CAS  Google Scholar 

  33. Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L (2003) Ligand-induced vascular endothelial growth factor receptor-3 (vegfr-3) heterodimerization with vegfr-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 278(42):40973–40979. doi:10.1074/jbc.M304499200

    Article  PubMed  CAS  Google Scholar 

  34. Naumnik W, Izycki T, Swidzinska E, Ossoliniska M, Chyczewska E (2007) Serum levels of vegf-c, vegf-d, and svegf-r2 in patients with lung cancer during chemotherapy. Oncol Res 16(9):445–451

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Authors do not have any conflict of interest.

Author information

Authors and Affiliations

  1. Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens, Greece

    Valsamo K. Anagnostou & Konstantinos N. Syrigos

  2. Laboratory of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Dina G. Tiniakos

  3. Department of Pathology, Sotiria General Hospital, Athens, Greece

    Marianthi Fotinou

  4. Third Department of Medicine, Sotiria General Hospital, Athens, Greece

    Apostolos Achimastos

Authors
  1. Valsamo K. Anagnostou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dina G. Tiniakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marianthi Fotinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Apostolos Achimastos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Konstantinos N. Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valsamo K. Anagnostou.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 13 kb)

ESM 2

(DOC 13 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anagnostou, V.K., Tiniakos, D.G., Fotinou, M. et al. Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients. Virchows Arch 458, 331–340 (2011). https://doi.org/10.1007/s00428-010-1015-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-010-1015-4

Keywords

Search

Navigation